The present invention is directed to a new class of 4-(oxoalkyl)phosphono, 4(oxime alkyl)phosphono, or 4-(hydrazine alkyl)phosphono, 2-piperazine carboxylic derivatives that are useful as NMDA antagonists
PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS
申请人:Paris Sciences et Lettres - Quartier Latin
公开号:EP3651758A1
公开(公告)日:2020-05-20
[EN] PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS<br/>[FR] PROBÉNÉCIDE POUR UTILISATION DANS LE TRAITEMENT DE MALADIES, TROUBLES OU AFFECTIONS ÉPILEPTIQUES
申请人:PARIS SCIENCES LETTRES QUARTIER LATIN
公开号:WO2019012109A1
公开(公告)日:2019-01-17
The present invention relates to probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in said subject. Preferably, said neurological disorder is an epileptic disease, disorder or condition.